INTRODUCTION
Previous studies have shown a strong association between hypothyroidism
and depressive disorders (1-3). Treatment-resistant depression (TRD) is
traditionally defined as depression with inadequate clinical response
usually following the traditional antidepressant therapy (4,5). Patients
with depression who fail to achieve symptom remission may pose
significant clinical challenges and need augmentation pharmacology
approach (4,5). We report a patient with TRD, hypothyroidism, and Thr92
Ala-DIO2 polymorphism who has responded well to T3
therapy, given in 3 divided doses.